VELOSEF Drug Patent Profile
✉ Email this page to a colleague
When do Velosef patents expire, and when can generic versions of Velosef launch?
Velosef is a drug marketed by Apothecon, Bristol Myers Squibb, and Ersana. and is included in five NDAs.
The generic ingredient in VELOSEF is cephradine. There are ten drug master file entries for this compound. Additional details are available on the cephradine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VELOSEF?
- What are the global sales for VELOSEF?
- What is Average Wholesale Price for VELOSEF?
Summary for VELOSEF
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 74 |
| Patent Applications: | 4,762 |
| DailyMed Link: | VELOSEF at DailyMed |
US Patents and Regulatory Information for VELOSEF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apothecon | VELOSEF | cephradine | CAPSULE;ORAL | 061764-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apothecon | VELOSEF | cephradine | INJECTABLE;INJECTION | 061976-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apothecon | VELOSEF | cephradine | INJECTABLE;INJECTION | 061976-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ersana | VELOSEF '500' | cephradine | CAPSULE;ORAL | 050548-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | VELOSEF | cephradine | TABLET;ORAL | 050530-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
